Celgene Paying Up To $2.6B In Jounce Cancer Collaboration
Biopharmaceutical company Celgene Corp. is infusing privately held Jounce Therapeutics Inc. with an upfront payment of $225 million, a $36 million equity investment and up to an additional $2.3 billion in...To view the full article, register now.
Already a subscriber? Click here to view full article